Mullen Automotive Acquires Controlling Interest in EV Truck Innovator Bollinger Motors, Inc.

With Nearly 50,000 Reservations for the Critically Acclaimed B1 and B2 Consumer Trucks, with Potential Customers and Upfitters Like Con Edison and Wabash, with Medium Duty Trucks Across Classes 3-6; Acquisition Accelerates Bollinger’s Delivery of Class 4 EV Trucks to 2023

Bollinger to Leverage Mullen’s Solid-State Battery Technology and Expertise

BREA, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today its acquisition of a controlling interest in EV truck innovator Bollinger Motors. This is Mullen’s first EV acquisition and propels the Company into the medium duty truck classes 3-6, along with the B1 and B2 sport utility trucks. The purchase price is $148.2 million in cash and stock for a 60% controlling interest, which gives Mullen the majority ownership of Bollinger Motors, Inc. and positions Bollinger to capture the electric sport utility and commercial vehicle markets. On Thursday, Sept. 8, at 2 p.m. EDT, Mullen Automotive and Bollinger Motors will host a live YouTube webinar introducing the two companies.

“This acquisition is one of the largest in the EV industry to date and provides Mullen with the unique opportunity to aggressively expand into the high-demand commercial EV space. The strong interest shown by major customers in all the high-volume segments like delivery, telecom, municipal services and utilities is a clear indication of the market’s desire for Bollinger’s vehicles,” said David Michery, CEO and chairman of Mullen Automotive. “Combining Bollinger’s vehicles with our existing class 1 and class 2 EV cargo van programs gives us the chance to dominate the entire class 1-6 commercial light and medium duty truck segments. In addition, Bollinger will be able to leverage Mullen’s solid-state battery technology, making their current vehicles even more competitive as our technology launches across the total portfolio of EVs from both Mullen and Bollinger.”

Launched in 2015, Bollinger Motors is an American automobile designer and manufacturer of electric sport utility and medium duty vehicle lines. The company also successfully developed proprietary vehicle battery packs, drivetrains, and thermal and vehicle control software units. In 2017, Bollinger built and debuted the critically acclaimed B1 class 3 sport utility vehicle, the first of its kind. The company followed its initial success with the development of the second-generation B1 and B2 vehicles, before pausing in favor of commercial truck development. With years of history in class 3 truck development, intellectual property, patents and expertise, the company’s decision made sense to pivot into commercial vehicle development for classes 3-6. As part of the acquisition, the company brings Mullen nearly 50,000 reservations previously taken for the B1 and B2 sport utility vehicles. With Mullen’s acquisition and capital injection, both B1 and B2 programs will begin after the start of production for class 3-6 commercial truck programs. A video presentation of Bollinger’s history can be found here.

The company brings a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets such as last mile delivery, refrigeration, utilities and their upfitters. On Sept. 1, 2022, Bollinger revealed for the first time the B4, a class 4 electric commercial truck. The B4 electric chassis cabs will be the first of the company’s commercial lineup to hit the ground in upcoming client test programs. The new Bollinger B4 incorporates years of feedback from dozens of major fleets looking to electrify their vehicles. The result is a cab-forward truck, designed from the ground up to offer maximum cargo volume, accommodate unlimited adaptation and prioritize safety. Bollinger will be testing B4 chassis cab trucks this fall with numerous fleet customers, upfitters and charging companies to gather constructive feedback. Further details on Bollinger’s B4 announcement can be found here.

“We are proud to design our commercial EVs from the ground up, here in America, offering greater efficiency, lower total cost of ownership and greater cargo volume. Our dream is to build the world’s best trucks and SUVs,” said Robert Bollinger, founder and CEO of Bollinger Motors. “Mullen shares a similar dream to build the best EV cars and trucks. This partnership will bring us closer to making those visions a reality, as it allows us to ramp up production on our end and get Mullen’s EV programs to the market faster.”

“We have been looking at this space carefully and raising the capital in advance, allowing us to take advantage of opportunities that arise,” added Michery. “We think Bollinger Motors is a perfect example of a smart investment in a known company and brand.”

“I am really impressed with what Robert Bollinger has created for the commercial vehicle space and the off-road capable B1 and B2 sport utility vehicles,” Michery continued. “Bollinger is a true innovator and generational company, and we believe they have the potential to turn the sector on its head, similar to what the Hummer H1 did over 30 years ago. Bollinger is a transformative acquisition and paradigm shift for the EV industry.”

Mullen Automotive and Bollinger Motors will be hosting a live webinar on Thursday, Sept. 8, at 2 p.m. EDT, introducing the two companies. Details on the YouTube event can be found here.

About Mullen Automotive
Mullen Automotive is a Southern California-based automotive company building the next-generation of premium electric vehicles (EVs) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the company, visit www.MullenUSA.com.

About Bollinger Motors
Founded in 2015 by Robert Bollinger, Bollinger Motors is a U.S.-based company, headquartered in Oak Park, Michigan. Bollinger Motors manufactures all-electric platforms and chassis cabs for commercial vehicles in Classes 3-6. To learn more about the company, visit www.BollingerMotors.com.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to whether the Bollinger majority ownership acquisition will be beneficial to the Company, whether Mullen will be successful in capturing market share in the electric sport utility and commercial vehicle markets, whether combining Bollinger’s vehicles with the Company’s existing class 1 and class 2 EV cargo van programs will be successful and whether the Company will achieve its goal of achieving a significant stake in the class 1-6 commercial light, medium and heavy-duty truck segments. Additional examples of such risks and uncertainties include whether Mullen’s solid-state battery technology development will be successful and will be able to be leveraged by Bollinger, if and when the Bollinger B1 and B2 sport utilities will be developed and whether the approximately 50,000 previous reservations for the B1 and B2 sport utilities will materialize. Further examples of such risks and uncertainties include but are not limited to: (i) Mullen’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Mullen’s ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Mullen’s ability to successfully expand in existing markets and enter new markets; (iv) Mullen’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Mullen’s business; (viii) changes in government licensing and regulation that may adversely affect Mullen’s business; (ix) the risk that changes in consumer behavior could adversely affect Mullen’s business; (x) Mullen’s ability to protect its intellectual property; and (xi) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.

Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4dcc413e-f0df-4bea-b12e-4daddc97649c
https://www.globenewswire.com/NewsRoom/AttachmentNg/56e59b55-7c70-4d42-b35a-ae3440bcd183
https://www.globenewswire.com/NewsRoom/AttachmentNg/7a52e8ea-85e9-495f-943d-6cd232102fdf

TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine.“The simple act of providing a whole genome sequence is likely the single most important piece of healthcare for a patient with a rare disease, and no child or family should have to needlessly suffer because they can’t afford it,” said Joshua Resnikoff, CEO and Cofounder of TMA Precision Health. “Our mission is to bring this service to those that need it most. We are thrilled to partner with Dante Genomics to bring the highest quality genomic sequencing and interpretation services to our patients around the globe.”Dante Genomics will provide 30X whole genome sequencing, clinical interpretation and personalized genomic reports to TMA’s patient network of more than 3.5 million people living with rare diseases for the purposes of diagnosis.

“There are so many people, especially children, suffering from undiagnosed rare diseases around the world, and it is this unmet need that we are working to serve every day,” said Andrea Riposati, CEO and co-founder of Dante Genomics. “We must work to end any diagnostic odyssey for these patients and reduce the time to diagnosis from years to days. Children with a rare disease, in any country, deserve the best clinical care, and TMA Precision Health is at the frontier to bring genomic driven care to the countries with the highest unmet need.”

Dante Genomics will utilize the genomic data related to this partnership to advance internal research related to novel target identification and drug development with the ultimate goal to go beyond diagnosis to treatment of rare disease.

TMA will incorporate the data from this partnership to continue growing the largest rare disease database in the world, with a focus on developing precision medicine solutions for rare patients everywhere.

About TMA Precision Health
TMA Precision Health is on a mission to provide personalized care and health equity for rare disease patients around the world. Our unique access to more than 3.5 million rare disease patients powers our ability to build on-demand comprehensive datasets of paired de-identified medical records and whole genomic sequencing and identify rare patients for clinical trials, giving our pharma partners a competitive edge when researching new insights and developing new treatments for this area of critically unmet need. For more information, please visit tmaprecisionhealth.com and follow us on LinkedIn.

About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contacts:
Joshua Resnikoff
CEO of TMA Precision Health
info@tmaprecisionhealth.com
www.tmaprecisionhealth.com

Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com

‫TMA Precision Health و Dante Genomics تدخلان في شراكة لمساعدة الأطفال المصابين بأمراض نادرة من خلال الحلول القائمة على تحديد التسلسل الجينومي السريريّ الكامل

نيويورك، 8 سبتمبر/أيلول 2022 (GLOBE NEWSWIRE) –أعلنت شركة Dante Genomics وهي الشركة الرائدة عالميًا في مجال علم الجينوميات والطب الدقيق اليوم عن عقدها شراكة مع شركة TMA Precision Health وهي شركة تهدف إلى تحسين حياة المرضى الذين يعانون من الأمراض النادرة في كل مكان، حيث تُحدّد التسلسل الجينومي السريري الكامل لمرضى الحالات النادرة كخطوة أولى في تشخيص المرض وعلاجه من خلال شخصنة الطب بشكل أوسع.

وقد صرح السيد Joshua Resnikoff، الرئيس التنفيذي والشريك المؤسس لشركة TMA Precision Health قائلاً “إن الأمر البسيط الذي يتمثل في توفير التسلسل الجينومي الكامل هو على الأرجح الجزء الأهم من الرعاية الصحية لمريض يعاني من مرض نادر، ولا ينبغي أن يعاني أي طفل أو أسرة بلا داع لكونهم لا يستطيعون تحمل التكلفة.” “وتكمن مهمتنا في تقديم هذه الخدمة لمن هم في أمس الحاجة إليها. يسعدنا الدخول في شراكة مع شركة Dante Genomics لتحديد التسلسل الجينومي بجودة عالية وتقويل النتائج لمرضانا في جميع أنحاء العالم”.

ستوفر شركة Dante Genomics اختبار تحديد التسلسل الجينومي الكامل 30X بالإضافة إلى تأويل نتائج التسلسل وسريرية وتقارير جينومية متخصصة لشبكة المرضى التابعين لشركة TMA والتي تضم أكثر من 3.5 مليون شخص يعيشون مع أمراض نادرة وذلك لأغراض التشخيص.

بينما أشار السيد Andrea Riposati، الرئيس التنفيذي والمؤسس المشارك لشركة Dante Genomics قائلاً “هناك أشخاص، كثيرون، خاصة من الأطفال، يعانون من أمراض نادرة لم يتم تشخيصها في جميع أنحاء العالم، وهي حاجة غير ملباة نعمل على توفيرها في كل يوم”. “We must work to end any diagnostic odyssey for these patients and reduce the time to diagnosis from years to days. يستحق الأطفال المصابون بأمراض نادرة، في أي بلد من البلدان أفضل رعاية سريرية ممكنة، وشركة TMA Precision Health تتبوأ مكانة رائدة في مجال تقديم الرعاية التي تعتمد على البيانات الجينومية إلى البلدان التي تعاني أكثر من الاحتياجات غير الملباة”.

ستستخدم شركة Dante Genomics البيانات الجينومية المتعلقة بهذه الشراكة لتعزيز البحث الداخلي المتعلق بتحديد أهداف علاجية جديدة وتطوير الأدوية بهدف تجاوز التشخيص وصولاً إلى علاج الأمراض النادرة.

ستدمج TMA البيانات الناتجة عن هذه الشراكة لمواصلة إعداد أكبر قاعدة بيانات للأمراض النادرة في العالم، مع التركيز على تطوير حلول الطب الدقيق لأصحاب الأمراض النادرة في كل مكان.

نبذة عن TMA Precision Health
تهدف شركة TMA Precision Health إلى توفير الرعاية المُشخصنة والمساواة الصحية للمرضى الذين يعانون من الأمراض النادرة في جميع أنحاء العالم. يعزز وصولنا الفريد إلى أكثر من 3.5 مليون مريض بأمراض نادرة من قدرتنا على بناء فئات بيانات شاملة عند الطلب من سجلات طبية مُقترنة ومطموسة الهوية والتسلسل الجيني الكامل وتحديد أصحاب الأمراض النادرة لغرض التجارب السريرية، مما يمنح شركائنا في مجال الأدوية ميزة تنافسية عند إجرائهم لأبحاث تستطلع الرؤى الجديدة وتطور علاجات جديدة لهذا المجال لتلبية الاحتياجات غير الملباة. لمزيد من المعلومات، يرجى زيارة الموقع الإلكتروني tmaprecisionhealth.com ومتابعتنا عبر LinkedIn.

نبذة عن شركة Dante Genomics
شركة Dante Labs هي شركة بيانات جينومية عالمية تختص ببناء وتسويق فئة جديدة من تطبيقات الصحة التحويلية وإطالة العمر بناءً على تحديد التسلسُل الجينومي الكامل ومن خلال استخدام الذكاء الاصطناعي. تستخدم الشركة منصتها لتحسين حصائل المرضى من خلال جهودها بدءً من التشخيص وحتى العلاج إعتمادًا على أصول لديها تتضمن واحدة من أكبر قواعد البيانات الجينومية الخاصة التي تم جمعها بموجب موافقات بحثية، وبرمجيات مسجلة الملكية مصممة لإطلاق العنان لقوة البيانات الجينومية على نطاق واسع، وعمليات مسجلة الملكية تتيح لنا اتباع نهج صناعي لتحديد التسلسُل الجينومي.

جهات الاتصال:
Joshua Resnikoff
الرئيس التنفيذي لشركة TMA Precision Health
info@tmaprecisionhealth.com
www.tmaprecisionhealth.com

Laura D’Angelo
نائبة الرئيس لعلاقات المستثمرين
ir@dantelabs.com
0671 191 0862 39+
www.dantegenomics.com